Media Statement re: New Hampshire's Decision to Overturn a New Hampshire U.S. District Court Ruling that Struck Down the State’s Law Banning the Commercial Use of Prescriber-Identifiable Data
PLYMOUTH MEETING, Pa., Nov. 18, 2008-SDI issued the following statement today regarding the First Circuit Court of Appeals’ decision to overturn a New Hampshire U.S. District Court ruling that struck down the State’s law banning the commercial use of prescriberidentifiable data.
“We are disappointed with the First Circuit Court of Appeals decision. Two federal courts previously have examined the issue and validated the view that the First Amendment protects the dissemination of prescriberidentifiable data, which we believe is vital to efforts to improve the quality, efficiency and safety of our healthcare system. We are currently reviewing the decision and evaluating potential next steps.”
On July 29th, 2008 Verispan, LLC was acquired by SDI. Since 1982, SDI has been delivering innovative healthcare data products and analytic services to the pharmaceutical, biotech, healthcare, medical device, financial services, and consumer packaged goods industries. SDI is the leading provider of deidentified patient-level data analytics and offers a broad array of solutions and insights across the continuum of care. These include custom and syndicated patient-level data studies; localized disease and treatment surveillance and projection; market research audits; healthcare profiles; comprehensive managed care offerings; clinical trial optimization; direct-topatient pharmacy programs; marketing effectiveness; sales targeting and compensation products; data integration, warehousing, and mining; list services; and direct marketing services. Its current roster includes the top 50 pharmaceutical/biotech companies. For more information, visit www.sdihealth.com or call 610.834.0800.
Posted: November 2008